FDA Approvals: A Year in Review by Lara Frick March 22, 2019Biosimilars, FDA, FDA Approvals, Magellan, Magellan Health, Magellan Healthcare, Magellan RX, Magellan Rx Management, New Drug Therapy Approvals, Novel drugs, Orphan Drugs, Rare Diseases
What do Employers Need to Know about Escalating Specialty Drug Spend? by Kathy Campagna May 24, 2017Autoimmune, Employers, Magellan Rx Management, Medical Benefit, Oncology, PBM, Rare Diseases, Specialty Pharmacy
Connecting Key Opinion Leaders with Prescribing Doctors – Enhancing Dialogue and Discussion by Maryam Tabatabai March 8, 2017Clinical Connections, Key Opinion Leader, Magellan Rx Management, Muscular Dystrophy, Rare Diseases
